Thorotrast is a radiographic contrast agent used in the past for medical imaging. Its spelling can be a bit perplexing, but using the International Phonetic Alphabet (IPA) can clarify how it's pronounced. The word is spelled with the "th" digraph representing the voiceless dental fricative sound /θ/. Next, the "or" diphthong gives the sound /ɔr/, followed by the unvoiced dental stop or plosive /t/. Finally, the word ends with the "ast" syllable pronounced as /æst/. Altogether, the word is pronounced as /ˈθɔrəˌtræst/.
Thorotrast is a highly specialized and now obsolete contrast agent that was used in medical imaging procedures, particularly in radiography and angiography. The substance is made up of thorium dioxide, also known as thorium(IV) oxide, which contains the radioactive isotope thorium-232.
Thorotrast was primarily employed to enhance the visibility and contrast of blood vessels, organs, and tissues during x-ray examination. However, its usage has been discontinued due to recognized long-term health risks. This compound was associated with severe health complications, particularly the development of cancers, predominantly hepatic cell carcinoma and leukemia.
As a contrast agent, Thorotrast was administered via injection directly into the blood vessels or tissues. Since the thorium-232 isotope is a potent emitter of alpha particles, its radioactive nature facilitated its detection within the body, thereby improving imaging quality. However, due to the high chemical toxicity and the prolonged presence of the substance, patients who had undergone Thorotrast injections faced significant health hazards.
Thorotrast was previously used for a period spanning several decades but eventually fell out of favor as safer and more effective alternatives became available. Despite its historical usage, this contrast medium serves as an example of the potential risks associated with certain chemical compounds utilized in medical practices of the past, and reinforces the importance of continuous improvements in medical imaging techniques to prioritize patient safety.
The word "Thorotrast" is derived from a combination of "thorium" and "contrast".
"Thorium" is a radioactive chemical element named after the Norse god of thunder, Thor. The element was discovered by Jöns Jacob Berzelius in 1828 and is commonly found in monazite sands. It is known for its high radioactivity and has various applications in nuclear technology and as an alloying element.
"Contrast" refers to the visual effect of highlighting differences or variations. In this context, it specifically relates to the use of a contrast agent in medical imaging.
When combined, "Thorotrast" denotes a contrast agent that contains thorium. Thorotrast was a radiographic contrast medium used in medical imaging from the 1930s to the 1950s.